All settlements
UpcomingProof TBD

Novo Nordisk, Eli Lilly

Ozempic, Wegovy Users Report Sudden Vision Loss in NAION Lawsuits

Patients allege GLP-1 drugs like Ozempic, Wegovy, and Mounjaro triggered a rare, often permanent eye condition and that makers failed to warn them, in a consoli

Key facts

Claim deadline
TBD
Potential payment
Up to $50,000
Proof requirement
TBD
Status
Upcoming

Eligibility

Who may qualify?

Check the covered dates, products, locations, and other official terms before you file.

  • You took a GLP-1 medication, and you were diagnosed with NAION or suffered sudden vision loss connected to that medication.

Case overview

What is the Novo Nordisk, Eli Lilly case about?

A group of federal lawsuits has been consolidated into a single proceeding known as multidistrict litigation, or MDL. Patients bringing the cases allege that popular GLP-1 medications caused a rare and serious eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION, sometimes referred to as an "eye stroke" because it can cause sudden and often permanent vision loss in one eye.

At the center of the litigation is the claim that drug makers failed to adequately warn patients and doctors of this risk. The companies deny wrongdoing and are fighting the allegations. No court has ruled on the claims, and whether these drugs actually cause NAION remains a matter of ongoing scientific debate.

Questions people ask

Frequently asked questions

How much is the Novo Nordisk, Eli Lilly case payout?

The listed potential payment is Up to $50,000. Final amounts depend on the number of valid claims and the administrator's terms.

Who qualifies for the Novo Nordisk, Eli Lilly case?

Key eligibility criteria include: You took a GLP-1 medication, and you were diagnosed with NAION or suffered sudden vision loss connected to that medication. Always confirm the full class definition with the official source before filing.

Is the Novo Nordisk, Eli Lilly case open for claims?

Not yet. No claim process is currently open. TapClaim monitors official updates to this case.

Settlement administrator and official sources

  • Listing verification
    Last checked Sep 23, 2026